Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study

M. Holubova, M. Miklikova, M. Leba, D. Georgiev, P. Jindra, M. Caprnda, R. Ciccocioppo, P. Kruzliak, D. Lysak,

. 2016 ; 142 (12) : 2561-2567. [pub] 20160910

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17013423

Grantová podpora
NV15-30661A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Leukaemia is an aggressive cancer of haematopoiesis. Despite increasing treatment success, the relapse rate is still high. Natural killer (NK) cells play a key role in the immune response to malignancies; thus, it is conceivable that NK cell-based immunotherapy may control relapses, while extending the disease-free survival. In our study, we investigated whether cryopreserved NK cells are able to kill the leukaemic K562 cell line, the necessity of IL-2 co-application and the association of activation marker expression (NKp44, NKG2D and CD25) with cytotoxic potential. MATERIALS AND METHODS: K562 cells were added to NK cell cultures in different ratios, i.e. 1:5, 1:10 and 1:20 (K562/NK), immediately after thawing NK cells or after 3-6-12-24 h of re-cultivation with or without IL-2. RESULTS: Our results demonstrated the ability of cryopreserved NK cells to kill K562 in all ratios, times and culture conditions. The number of dead K562 cells depended on the number of NK cells and on the presence of IL-2. NK cells cytotoxic potential decreased gradually in the culture without IL-2. In contrast, NK cell-mediated cytotoxicity remained the same during the entire re-culture period after IL-2 re-application. CONCLUSION: Our study proved the efficacy of using cryopreserved ready-for-use NK cells in relapse treatment and the need for simultaneous administration of IL-2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013423
003      
CZ-PrNML
005      
20201102153731.0
007      
ta
008      
170413s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00432-016-2247-8 $2 doi
035    __
$a (PubMed)27614454
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Holubova, Monika $u Department of Haematology and Oncology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic. holubovam@fnplzen.cz. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. holubovam@fnplzen.cz. Department of Haematology and Oncology, Faculty Hospital in Pilsen, Charles University in Prague, Alej Svobody 80, 304 60, Pilsen, Czech Republic. holubovam@fnplzen.cz.
245    10
$a Cryopreserved NK cells in the treatment of haematological malignancies: preclinical study / $c M. Holubova, M. Miklikova, M. Leba, D. Georgiev, P. Jindra, M. Caprnda, R. Ciccocioppo, P. Kruzliak, D. Lysak,
520    9_
$a BACKGROUND: Leukaemia is an aggressive cancer of haematopoiesis. Despite increasing treatment success, the relapse rate is still high. Natural killer (NK) cells play a key role in the immune response to malignancies; thus, it is conceivable that NK cell-based immunotherapy may control relapses, while extending the disease-free survival. In our study, we investigated whether cryopreserved NK cells are able to kill the leukaemic K562 cell line, the necessity of IL-2 co-application and the association of activation marker expression (NKp44, NKG2D and CD25) with cytotoxic potential. MATERIALS AND METHODS: K562 cells were added to NK cell cultures in different ratios, i.e. 1:5, 1:10 and 1:20 (K562/NK), immediately after thawing NK cells or after 3-6-12-24 h of re-cultivation with or without IL-2. RESULTS: Our results demonstrated the ability of cryopreserved NK cells to kill K562 in all ratios, times and culture conditions. The number of dead K562 cells depended on the number of NK cells and on the presence of IL-2. NK cells cytotoxic potential decreased gradually in the culture without IL-2. In contrast, NK cell-mediated cytotoxicity remained the same during the entire re-culture period after IL-2 re-application. CONCLUSION: Our study proved the efficacy of using cryopreserved ready-for-use NK cells in relapse treatment and the need for simultaneous administration of IL-2.
650    _2
$a kultivované buňky $7 D002478
650    12
$a kryoprezervace $7 D015925
650    12
$a cytotoxicita imunologická $7 D003602
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie adoptivní $x metody $7 D016219
650    _2
$a buňky K562 $7 D020014
650    _2
$a buňky NK $x imunologie $7 D007694
650    _2
$a leukemie $x terapie $7 D007938
650    _2
$a aktivace lymfocytů $7 D008213
655    _2
$a časopisecké články $7 D016428
700    1_
$a Miklikova, Michaela $u Department of Haematology and Oncology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
700    1_
$a Leba, Martin $u New Technologies for the Information Society European Centre of Excellence, Faculty of Applied Sciences, University of West Bohemia, Pilsen, Czech Republic.
700    1_
$a Georgiev, Daniel $u New Technologies for the Information Society European Centre of Excellence, Faculty of Applied Sciences, University of West Bohemia, Pilsen, Czech Republic.
700    1_
$a Jindra, Pavel $u Czech National Bone Marrow Donor Registry (CS-2), Pilsen, Czech Republic.
700    1_
$a Caprnda, Martin $u 2nd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
700    1_
$a Ciccocioppo, Rachele $u Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.
700    1_
$a Kruzliak, Peter $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Palackeho tr. 1/1946, 612 42, Brno, Czech Republic. kruzliakpeter@gmail.com.
700    1_
$a Lysak, Daniel $u Department of Haematology and Oncology, Medical School and Teaching Hospital in Pilsen, Charles University in Prague, Pilsen, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
773    0_
$w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 142, č. 12 (2016), s. 2561-2567
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27614454 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20201102153730 $b ABA008
999    __
$a ok $b bmc $g 1199888 $s 974201
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 142 $c 12 $d 2561-2567 $e 20160910 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972
GRA    __
$a NV15-30661A $p MZ0
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace